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Abstract
Heparin has been the most commonly used anticoagulant drug for nearly a century. The drug
heparin is generally categorized into three forms according to its molecular weight (MW),
unfractionated (UF, average MW 13,000), low molecular weight (LMW, average MW 5,000), and
ultra-low molecular weight heparin (ULMWH, average MW 2,000). Overdose of anticoagulant
heparin can lead to very dangerous bleeding in patients. Protamine sulfate can be administered as
an antidote to reverse heparin’s anticoagulant effect. There is not an effective antidote for
ULMWH. In the current study, we examine human N-acetylglucosamine 6-sulfatase (NG6S),
expressed in Chinese hamster ovary cells as a reversal agent for ULMWH. NG6S removes a
single 6-O-sulfo group at the non-reducing end of the ULMWH Arixtra® (fondaparinux)
effectively removing its ability to bind to antithrombin and preventing its inhibition of coagulation
factor Xa. These results pave the way to develop human NG6S as an antidote for neutralizing the
anticoagulant activity of ULMWHs.
Introduction
Heparin is a member of glycosaminoglycan family, consisting of the repeating disaccharide
unit of iduronic acid (IdoA)/glucuronic acid (GlcA) linked with glucosamine (GlcN) with
sulfo group substituents on both saccharide units [1]. Glycosaminoglycans often have
distinctive structural domains associated with the presence of N-sulfo (NS) or N-acetyl (NA)
glucosamine residues, including NS domains, mixed NA/NS domains and NA domains
[2,3]. Heparin is primarily comprised of long blocks of NS domains that also contain a high
level of O-sulfo groups that are responsible for its binding to proteins, such as antithrombin
III (AT) [4–6]. Moreover, the AT-binding domain is comprised of a sulfated
pentasaccharide sequence within heparin having a highly conserved, and well-studied
sequence [7].
Heparin has been used clinically as an anticoagulant since its discovery in 1916 [2,8]. It is
widely applied in therapy for treatment of deep vein thrombosis, hip surgery, knee
replacement surgery, blood transfusions, and renal dialysis [9]. The drug heparin is generally
classified into three forms according to its molecular weight (MW), unfractionated (UF,
average MW 13,000), low molecular weight (LMW, average MW 5,000), and ultra-low
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molecular weight heparin (ULMWH, average MW 2,000) [9,10]. UF heparin is prepared
from animal tissues, such as porcine intestine and LWW heparins are prepared through the
controlled chemical or enzymatic depolymerization of UF heparin [11]. In 2008, a serious
contamination issue of pharmaceutical heparin affected 12 countries, and was associated
with an estimated 200 deaths around the world [10,12]. Unlike UF heparin and LMW
heparins, ULMWH, such as Arixtra® (fondaparinux), can be made through chemical
synthesis [11], avoiding the potential contamination issue associated with animal products.
The ULMWH fondaparinux has a number of advantages when compared with UF heparin. It
is subcutaneously active, has a longer half-life improving its pharmacokinetics and
fondaparinux exhibits a reduced incidence of heparin-induced thrombocytopaenia (HIT)
[13–15]. One advantage of UF heparin, however, is that, it can be reversed through the
administration of an antidote, protamine sulfate. Protamine sulfate is a basic polypeptide-
based drug that tightly binds UF heparin neutralizing its activity but does not bind the
smaller ULMWH with sufficient avidity to reverse its activity [16]. Overdose of
anticoagulants can lead to very dangerous bleeding in patients so that reversal of
anticoagulant activity is necessary. If bleeding after an overdose of the ULMWH
fondaparinux occurs, the only method to remove it is through the relatively aggressive
procedure of renal dialysis [16]. A more convenient and safe method for the removal of
ULMWH from the blood is critically needed when such an overdose occurs.
N-acetylglucosamine 6-sulfatase (NG6S) is a lysosomal enzyme that is involved in the
natural catabolism of glycosaminoglycans in the body [17]. NG6S is a highly glycosylated,
divalent metal ion-dependent, exolytic sulfatase [18–20] that hydrolyzes a sulfo group from
a non-reducing terminal 6-O-sulfated glucosamine residue [21,22]. In the current study, we
present a novel approach for the neutralization of fondaparinux and another ULMWH,
ULMWH1 [9] (Figure 1A), using recombinant human NG6S to remove a 6-O-sulfo group
from their non-reducing termini. These 6-O-desulfated products are expected to lose their
binding affinity to AT and, thus, to lose their anticoagulant activity [7].
Results and discussion
NG6S expression, purification and determination of activity
Recombinant NG6S was prepared by cloning a portion of the human NG6S (T44-L552)
gene comprising its catalytic domain into a pSecTag2 vector. The cloned plasmid was
transformed into Chinese hamster ovary (CHO) cells and the cells were grown in F12
medium supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37°C
under 5% CO2 for 2 to 3 days. Supernatant containing NG6S activity, as determined using
4-nitrocatecholsulfate (PNCS) as substrate, was pooled and concentrated with YM-10 filter.
The concentrated solution, high in NG6S activity, was purified by fast protein liquid
chromatography (FPLC) using a strong cationic exchanger Mono-S column. The fractions
with NG6S activity were pooled and analyzed with Western Blotting technology using anti-
myc antibody (as shown in Figure 1B, C).
Two different ULMWHs, fondaparinux and ULMWH1 (Figure 1A), were used in this study
as substrates for NG6S. ULMWH1 was prepared as previously described [9] and
fondaparinux was purchased from local pharmacy. ULMWH1 and fondaparinux both
contain an AT-binding site and are terminated at their non-reducing ends with 6-O-sulfo-N-
acetylglucosamine and 6-O-sulfo-N-sulfoglucosamine, respectively. Treatment at 37 °C
overnight with NG6S (4 μg of protein), in 100-μL of 50 mM sodium acetate, pH 5.0 buffer
containing 250 mM NaCl and 100 μg/ml bovine serum albumin, completely removed the 6-
O-sulfo group from the non-reducing glucosamine residue of 1 μg of ULMWH.
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Determination of the desulfation site by NG6S
The susceptibility of ULMWH1 to NG6S digestion was determined by measuring the
retention time of 35S-labeled ULMWH1 on high resolution diethylaminoethyl (DEAE)-high
performance liquid chromatography (HPLC). Undigested ULMWH1 eluted at 45 min (at
1000 mM NaCl), while the completely digested ULMWH1 eluted at 40 min (at 900 mM
NaCl) as shown in Figure 2A, B. This altered elution time suggested that ULMWH1 had lost
a single sulfo group on digestion with NG6S.
We next tested whether NG6S could act on ULMWH1 in the presence of AT. AT is known
to tightly bind ULMWHs with nanomolar affinities [9] initiating anticoagulation. The
plasma concentration of AT is ~2μg/ml [23] suggesting that in order for NG6S to reverse
ULMWH anticoagulant activity it must drive the AT-bound and free ULMWH towards free
form. Various concentrations of AT (from 0 to 800μg/ml) were incubated for 30 min. at
room temperature before adding NG6S to initiate the reaction. The results clearly
demonstrate that NG6S can efficiently act on ULMWH1 even at AT concentrations as high
as 80 μg/ml (Figure 2C). Significant amounts of ULMWH1 could even be 6-O-desulfated at
AT concentrations as high as 400 and 800 μg/ml (as shown in Figure 2D, 2E). A time-
course for digestion of UMLWH1 with NG6S is shown in Figure 3.
The structure of the NG6S-treated ULMWH1 was next analyzed by mass spectrometry
(MS) to confirm the number and position(s) of sulfo groups that had been hydrolyzed. The
molecular mass measurement of untreated and NG6S-treated ULMWH1 indicated a
decrease in mass by 79.9544 Da (4 × (459.7487–439.7601) = 79.9544), corresponding to the
loss of a single sulfo group from ULMWH1 after NG6S-treament (Figure 4). MS/MS
analysis was next used to determine which sulfo group had been lost. Comparison of the
MS/MS fragmentation patterns of untreated and NG6S-treated ULMWH1 demonstrates that
the 6-O-sulfo group at the non-reducing end of ULMWH1 was lost (Figure 5). The MS/MS
signal of m/z 198.9916 in the untreated ULMWH1 confirmed the presence of a 6-O-sulfo
group (0,2A1 fragment [24]) on the non-reducing end. After the NG6S-treatment, the peak at
m/z 198.9916 disappeared, unambiguously demonstrating that this 6-O-sulfo group had been
lost from the saccharide residue at the non-reducing end. NG6S-treatment also resulted in
the disappearance of the B1 and C1 ions. The (Y5+6Na)2− fragment, detected in the both
NG6S-treated and NG6S-untreated ULMWH1, clearly demonstrating that there was no
additional sulfo group loss from any of the other saccharides after the NG6S-treatment.
Thus, as expected, NG6S removes a single 6-O-sulfo group from the non-reducing end
GlcNAc6S residue of ULMWH1.
NG6S treatment of ULMWHs eliminates AT-binding and reverses anticoagulant activity as
measured by anti- factor Xa assay
ULMWH binds to AT and results in AT undergoing a conformational change, causing AT to
become a potent inhibitor of coagulation factor Xa [25]. We next examined if NG6S
treatment of ULMWHs, ULMWH1 and fondaparinux, could eliminate their AT-binding and
reverse their anti-Xa activities. First, we examined the binding of NG6S-treated and
untreated ULMWHs to AT. 35S-labeled ULMWH1 and 35S-labeled ULMWH1a (ULMWH1
lacking a 3-O-sulfo group, Figure 1A) and 35S-labeled fondaparinux were prepared.
ULMWH1a serves as a negative control as it does not bind to AT [26]. These samples were
subjected to an AT-affinity chromatography to determine the percentage of bound
radiolabel. The results show that AT-binding of 35S-labeled ULMWH1 dropped from 60%
to 5% after removing the terminal 6-O-sulfo group, AT-binding of 35S-labeled fondaparinux
dropped from 80% to < 5% (Fig 5). The AT-binding level of the negative control using 35S-
labeled ULMWH1a was approximately 5% (Figure 6). These results confirm that NG6S
treatment of ULMWHs greatly reduced their binding affinity for AT.
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Nanomolar concentrations ULMWH1 and fondaparinux strongly inhibit factor Xa activity in
the presence of AT, as determined by anti-Xa activity assay. As expected based on their loss
of AT-binding affinity, both ULMWHs displayed no anti-Xa activity following NG6S
removal of the 6-O-sulfo group (Figure 7). In this experiment, heparan sulfate obtained from
bovine kidney was used as a negative control as it has no anti-Xa activity [27]. These data
clearly demonstrate that NG6S effectively eliminates the binding of two ULMWHs by
hydrolyzing the 6-O-sulfo group from the non-reducing terminal glucosamine residues,
resulting in oligosaccharides having no anti-Xa activity.
The activity of NG6S at different pHs
We determined the sulfatase activity of NG6S using the synthetic substrate, PNCS, at
different pHs (Fig 8A). As expected, the optimal pH for NG6S is at pH 5, consistent with
the general property for a lysosomal protein. We then compared the susceptibility of
ULMWH1 to NG6S digestion at pH5.0 and pH7.0 (Fig 7B and 7C). As expected, a
complete digestion of ULMWH1 was observed when the digestion was carried out at pH
5.0, while only 15 to 20% of ULMWH1 was digested under pH 7.0. Our data demonstrate
that lower digestion efficiency was observed for NG6S at physiological pH.
Conclusions
The widely used anticoagulants, UF heparin, LMW heparin and the ULMWH,
fondaparinux, have a worldwide market size of several billion dollars/year [28]. ULMWHs
are unique among this group of anticoagulants as they are synthesized as homogenous
compounds using a chemical or a chemoenzymatic approaches [9,29]. Arixtra® was
approved by the US Food and Drug Administration in 2001 and a generic fondaparinux was
approved in 2011. An overdose of UF heparin and, to a lesser degree, an overdose of LMW
heparins can be reversed through the administration of the antidote, protamine sulfate. One
major problem associated with the use of fondaparinux and other ULMWHs is the lack of a
similar antidote. Thus, developing an antidote for ULMWHs is very important for
improving the safety of this class of heparin-based anticoagulant drugs. In the current study,
we describe a novel approach to remove the anti-Xa activities of ULMWH1 and
fondaparinux using NG6S. While this method might one day be implemented as an antidote
for fondaparinux and other ULMWHs, there are certain limitations. First, the structure of
ULMWH is critically important for its susceptibility to NG6S neutralization requiring the 6-
O-sulfoglucosamine residue of the AT-binding site to reside at the non-reducing terminus of
the ULMWH being reversed. Second, since NG6S is a lysosomal enzyme, its pH optimum is
approximately 5.0 [30]. Thus, at a physiological pH of 7, the activity of NG6S is
significantly reduced. Either a substantial amount of NG6S will be required for in vivo
neutralization of ULMWH or protein engineering will be required to shift the pH optimum
of NG6S as demonstrated in other enzymes [31].
Materials and Methods
Protein expression and purification
Full length human N-acetylglucosamine 6-sulfatase NG6S (Clone ID# 4515104) was
purchased from Open Biosystem. The catalytic domain (T44-L552) was cloned into
pSecTag2 using Hind III and XhoI sites. The expression plasmid pSecTag2-NG6S was
transfected into wild-type CHO cells using LipofectAMINE 2000 (Invitrogen) following the
manufacturer’s protocol. The cells were grown in F12 medium supplemented with 10% fetal
bovine serum and appropriate antibiotics Penicillin/Streptomycin at 37°C under 5% CO2 for
2 to 3 days. The supernatant was pooled and subjected for protein purification.
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NG6S was partially purified as described previously [22]. Briefly, the supernatant was
concentrated to approximately 5 ml using YM-10 filter. Ion-exchange chromatography was
performed using FPLC system on a strong cationic exchanger Mono-S pre-packed column
(0.5 × 10 cm) equilibrated with 0.1 M sodium acetate, pH 4.0. The bound proteins were
eluted with a linear gradient from 0 to 1.0 M NaCl in 0.1 M sodium acetate, pH 4.0. NG6S
activity from different fraction collection tubes was determined using 4-nitrocatecholsulfate
(PNCS) as substrate and the samples with high NG6S activity were pooled and stored at
−80°C until use.
Western blot analysis of the purified NG6S
Eluant (10 μl) from each fraction collection tube having NG6S activity was analyzed on
15% sodium dodecylsulfate-polyacrylamide gel electrophoresis. ECL-protein molecular
weight markers (2 μl) were used. After electrophoresis protein was transferred to
nitrocellulose membrane (Amersham Pharmacia Biotech) and detected using mouse anti-
myc antibody (Invitrogen) followed by horseradish peroxidase conjugated anti-mouse IgG
secondary antibody (Amersham Biosciences). ECL Western Blotting Detection Reagents
(Amersham Biosciences) was used to induce chemiluminescence and the blot was exposed
to X-ray film for 15 min.
Degradaton of ULMWH by NG6S
The degradation of ULMWH by active NG6S was carried out in the reaction buffer (50 mM
sodium acetate, pH 5.0; 250 mM NaCl; 100 μg/ml BSA) at 37°C. When necessary, 2 mM of
PNCS was used as substrate instead of ULMWHs, and absorbance was read at 490 nm.
HPLC analysis
The product was resolved by a TSKgel DNA-NPR HPLC column (0.46 × 7.5 cm; Tosoh
Bioscience) with radioisotope detection. The elution conditions for the HPLC analysis were
described elsewhere [26]. Briefly, the column was eluted with NaCl as follows: 0 M for 10
min followed by gradient NaCl (0 to 1 M) for 30 min, followed by 1 M for 15 min, followed
by 0 M for 10 min, in a solution containing 20 mM Tris-HCl, pH 7.0.
MS analysis
A Thermo Scientific LTQ Orbitrap XL FT mass spectrometer with a standard, factory-
installed nano-spray ion source (Thermo Scientific) was used in these experiments.
ULMWH1 and NG6S-treated ULMWH1 (~2 μM) in 50:50 methanol: water with 1.0 mM
NaOH was used for analysis [32]. Negative-ion mode electrospray ionization was used to
ionize the sample. The optimized parameters, used to prevent in-source fragmentation,
included a spray voltage of 1.2 kV, a capillary voltage of 40 V, a tube lens voltage of 50 V,
a capillary temperature of 250 °C. External calibration of mass spectra routinely produced a
mass accuracy of better than 3 ppm. All FT mass spectra were acquired at a resolution
60,000 with 350–1500 Da mass range. MS/MS product ions are generated by collisionally-
induced dissociation fragmentation. Peaks were assigned using from their accurate mass
measurement values with the help of the software package GlycoWorkbench 2.0. [33]
Preparation 35S-labeled oligosaccharides
The preparations of 35S-labeled ULMWH1 and ULMWH1a are described in a previous
publication [9]. For ULMWH1, the 35S-label is present at the 3-O-sulfo group; while for
ULMWH1a, the 35S-label is present at the 6-O-sulfo groups. The preparation of 35S-labeled
fondaparinux was completed by incubating 3-OST-1 enzyme, [35S]PAPS and
fondaparinux-3-OH substrate (a generous gift from Dr. Petitou) [34]. A disaccharide
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analysis was performed to ensure the appropriate sulfation using the method reported by
Karamonos and colleagues[35].
AT Binding
Assays were based on a previously published method [27]. Approximately 1 × 105 cpm
[35S] labeled ULMWHs were incubated with 5 μg AT in 50 μl of reaction buffer containing
10 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1 mM Mn2+, 1 mM Mg2+, 1 mM
Ca2+, 10 μM dextran sulfate, 0.02% sodium azide and 0.0004% Triton X-100 for 30 min at
room temperature. A 60 μl 1:1 slurry of pretreated Concanavalin A-Sepharose (from Sigma)
was added, and the reaction was agitated for 1 hour at room temperature on an orbital
shaker. The beads were washed three times with the reaction buffer and eluted with buffer
containing 10 mM Tris-HCl (pH 7.5), 1000 mM sodium chloride, 1 mM Mn2+, 1 mM Mg2+,
1 mM Ca2+, 10 μM dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100.
Determination of Anti-Xa activity
Assays were based on a previously published method [27,36]. Briefly, bovine factor Xa
(Sigma) was diluted to 5 U/ml (about 80 nM) with PBS containing 1 mg/ml BSA. Human
AT (Cutter Biological) was diluted with PBS containing 1 mg/ml BSA to give a stock
solution at the concentration of 0.4 μM. The chromogenic substrates, S-2765 was from
Diapharma and made up at 1.3 mM in water. The oligosaccharide (fondaparinux, ULMWH)
was dissolved in PBS at various concentrations (0 to 100 nM). The reaction mixture, which
consisted of 80 μl of AT stock solution and 15 μl of the solution containing the sample, was
incubated at 37°C for 2 min. Factor Xa (10 μl) was added. After incubating 37°C for 4 min,
30 μl of S-2765 was added. The absorbance of the reaction mixture was measured at 405 nm
continuously for 10 min. The absorbance values were plotted against the reaction time. The
initial reaction rates at varying ULMWH concentrations were converted to an activity
percentage based on the initial rate of the reaction without ULMWH. The ratios were plotted
against ULMWH concentrations.
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Abbreviations
AT antithrombin III
CHO Chinese hamster ovary
DEAE diethylaminoethyl
FPLC fast protein liquid chromatography
GlcN glucosamine
GlcA glucuronic acid
HIT heparin induced thrombocytopenia
HPLC high performance liquid chromatography
IdoA iduronic acid
LMW heparin low-molecular weight heparin
MS mass spectrometry
MW molecular weight
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UF heparin unfractionated heparin
ULMWH ultra-low molecular weight heparin
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NG6S purification and activity determination. (A) Structure of ULMWHs (ULMWH1 and
fondaprinux) and an AT-binding-negative ULMWH construct (ULMWH1a). The non-
reducing end 6-O-sulfo group (colored in blue) can be removed by NG6S digestion. 35S-
labeled constructs were also used in this study. The 35S-label for ULMWH1 and
fondaparinux was at the 3-O-sulfation (colored in red) position. The 35S-label (colored in
red) for ULMWH1a was at the 6-O-sulfation. (B) Activity profile of NG6S from mono S-
column. The activity was measured using PNCS as the substrate. (C) Western Blot assay of
the partially purified protein in fraction collection tubes (tube 10–20) with anti-myc
antibody. A protein band at 62 KDa was detected, consistent with the estimated molecular
weight of recombinant NG6S.
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DEAE-HPLC profiles of ULMWH1 treated with NG6S in the presence of AT. ULMWH1
was incubated with different amount of AT for 30 min in the reaction buffer at room
temperature, then NG6S was added. After overnight digestion, the sample was purified with
DEAE Sepharose column eluted with a sodium chloride gradient (0 to 1.0 M NaCl, pH 7.0
mM) at a flow rate of 0.4-mL/min. ULMWH1 mixed with less than 80 μg/ml of AT can be
completely digested, and more than 50% ULMWH1 mixed with 400 μg/ml of AT can be
digested.
Zhou et al. Page 10














Time-course of ULMWH1 digestion by NG6S. Panel A shows the DEAE-HPLC
chromatogram of undigested ULMWH1 (45 min). Panel B shows the DEAE-chromatogram
of the ULMWH1 digested with NG6S for six hours showing a new peak at 40 min). Panel C
shows the DEAE-HPLC chromatogram of the ULMWH1 completely digested with NG6S
overnight.
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MS analysis of ULMWH1. NG6S removes one sulfo group from ULMWH1. Accurate MS
analysis indicated that after NG6S-treament mass decreased by 79.9544 Da corresponding to
the loss of a single sulfo group from ULMWH1. Sodium adducts observed as clusters,
which is common for highly negatively charged ULMWH.
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MS/MS analysis of ULMWH1. The specific loss of 6-O-sulfo group at the non-reducing end
of ULMWH1 can be confirmed by MS/MS analysis. The MS/MS signal of 198.9916
(0,2A11- fragment) in the untreated ULMWH1 confirms the presence of a 6-O-sulfo group
(colored in red) at the non-reducing end. After the NG6S-treatment the peak at 198.9916
disappeared as did the C1 ion. The (Y5-2H+6Na)2− fragments, detected in the both NG6S-
treated and untreated ULMWH1, demonstrate no nonspecific sulfo group loss from the other
sugars on NG6S treatment.
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The AT binding of NG6S treated fondaparinux and ULMWH1. 35S-labeled oligosaccharides
were digested with NG6S and purified with DEAE-Sepharose column. The 35S-labeled
ULMWH1a without AT-binding affinity was used as negative control. After NG6S
treatment, the levels of AT-binding in ULMWH1 and fondaparinux were reduced to that of
the negative control.
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Anti-Xa activity of NG6S digested ULMWH1 and fondaparinux. Oligosaccharide was
digested with NG6S and purified with DEAE Sepharose column. Bovine kidney heparan
sulfate without anti-Xa activity was used as negative control. NG6S digestion removes anti-
Xa activity of ULMWH1 and fondaparinux.
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The activity of NG6S at different pHs. Panel A shows the activity of NG6S toward a
synthetic substrate, PNCS, at different pHs. Panel B shows the DEAE-HPLC chromatogram
of ULMWH1 digested with NG6S at pH 5. Panel C shows the DEAE-HPLC chromatogram
of ULMWH1 digested with NG6S at pH 7. The elution positions of ULMWH1 and digested
ULMWH1 are indicated.
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